Market News AIOpen the app

Recursion Pharmaceuticals is working with the FDA on a Phase 3 trial plan for its drug REC-4881 to treat familial adenomatous polyposis.

TrialRead the original at globenewswire.com
Good for RXRX

Recursion agreed with the FDA on a Phase 3 study plan for REC-4881, giving the drug a clearer path to testing. The study is not expected to start until the second half of 2027, and no trial results are reported.

RXRX · Recursion Pharmaceuticals

AI read · Good for RXRX

The AI's read

This gives Recursion a clearer route to test whether REC-4881 helps patients with FAP. The study will track polyp growth and removal, but it is not expected to start until the second half of 2027. Recursion estimates a possible $15 billion market, but that figure does not prove the drug will work or find buyers.

Get alerts for RXRX

Follow Recursion Pharmaceuticals (RXRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RXRX
Free on the App Store and Google Play, or on the web.